Aytu biopharma announces peer-reviewed publication of clinical results from healight(tm) pilot study

Results indicate that endotracheal uva light catheter therapy is associated with significant reduction in sars-cov-2 viral load and improvement in clinical outcomes in mechanically ventilated covid-19 patients englewood, co / accesswire / june 28, 2021 / aytu biopharma, inc. (nasdaq:aytu), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that data from the first in-human, open label, clinical trial studying the safety and effectiveness of ultraviolet a (uva) light endotracheal catheter therapy was published online on june 26, 2021 in the peer-reviewed journal advances in therapy. the uva light catheter technology utilized in this study is the basis of aytu biopharma's healight™ medical device which has been exclusively licensed worldwide for all endotracheal and nasopharyngeal applications.
AYTU Ratings Summary
AYTU Quant Ranking